THE LANCET Global Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Liu L, Villavicencio F, Yeung D, et al. National, regional, and global causes of mortality in 5–19-year-olds from 2000 to 2019: a systematic analysis. *Lancet Glob Health* 2022; **10:** e337–47.

Table of contents

| webappendix 1. Country classification | , 3 |
|--|------------|
| Webappendix 2. Cause categorization and ICD codes | 7 |
| Webappendix 3. Model input data procurement and preparation | 8 |
| Webappendix 3.1 Covariates and their preparation | 8 |
| Webappendix 3.2 COD model inputs preparation | 11 |
| Webappendix 3.3 Input data map | 14 |
| Webappendix 4. Additional details of modeling and estimation | 15 |
| Webappendix 4.1 The Bayesian LASSO | 15 |
| Webappendix 4.2 Estimation of the sex-specific deaths and rates for 15-19 | 16 |
| Webappendix 4.3 Point estimates and uncertainty | 17 |
| Webappendix 4.4 Transparency and replicability | 18 |
| Webappendix 5. Modeling and estimation strategies | 19 |
| Webappendix 6. Additional details on single cause estimates | 20 |
| Webappendix 6.1 Splitting measles into endemic and epidemic | 20 |
| Webappendix 6.2 The process of squeezing extrapulmonary TB, HIV/AIDS and endemic measles into Other CMPN | |
| Webappendix 6.3 Crisis estimates | 21 |
| Webappendix 7. The GATHER checklist | 22 |
| Webappendix 8. Inputs and outputs by estimation methods | 23 |
| Webappendix 9. Model selection process | 24 |
| Webappendix 9.1 Cross-validation for low-mortality model (LMM) | 24 |
| Webappendix 9.2 Cross-validation for high-mortality model (HMM) | 25 |

| Webappendix 10. Global and regional cause-specific mortality estimates by age-sex group, 2000-2019 | . 26 |
|--|------|
| Webappendix 10.1 Data files with global and regional cause-specific mortality estimates | 26 |
| Webappendix 10.2 Global and regional leading causes of death 5-19 years in 2019 | 27 |
| Webappendix 10.3 Global and regional causes of mortality fractions by age-sex group in 2019 | 28 |
| Webappendix 10.4 Regional cause-specific mortality rates by age-sex group, time trends 2000-2019 | 32 |
| Webappendix 11. National cause-specific mortality estimates by age-sex group, 2000-2019 | 41 |
| Webappendix 11.1 Data files with national cause-specific mortality estimates | 41 |
| Webappendix 11.2 Countries with the highest number of deaths in 2019 | 42 |
| Webappendix 11.3 Cause-specific mortality rates by age-sex group in India, Nigeria and Democratic Republic of Congo, time trends 2000-2019 | 43 |
| References | 46 |

Webappendix 1. Country classification

High-quality VR countries were based on WHO criteria on the quality, completeness of vital registration (VR) data for ages 15 and above, and usability.¹

We used a 10/1000 mortality rate in 2010 from 5 to 20 years of age from UN-IGME² as the threshold that separates low and high mortality model countries. The mortality rate between ages 5 and 20 years, denoted as $_{15}q_5$, is defined as the probability of dying between exact ages 5 and 20, expressed per 1,000 population aged 5.² We identified percentiles aligned with those used for the country classification for children under-five: $^310/1000$ is the 70 percentile of $_{15}q_5$ for all countries, and the 50 percentile of $_{15}q_5$ for all countries excluding those with high-quality VR data in 2010.

Below is the list of the 195 countries for which we provide cause-of-death estimates. The table also includes their regional classification, model category, and whether they have been flagged as a fragile state.⁴ These are the same 195 countries for which UN-IGME provides estimates, which corresponds to the 194 WHO member states plus the West Bank and Gaza Strip.²

Table S1. List of the 195 countries and their classification

| ISO3 | WHO name | Region | Model category | Fragile state |
|------|----------------------------------|---------------------------------|----------------------------|---------------|
| AFG | Afghanistan | South Asia | High mortality model (HMM) | YES |
| AGO | Angola | Eastern and Southern Africa | High mortality model (HMM) | NO |
| ALB | Albania | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| AND | Andorra | Western Europe | Low mortality model (LMM) | NO |
| ARE | United Arab Emirates | Middle East and North Africa | Low mortality model (LMM) | NO |
| ARG | Argentina | Latin America and Caribbean | High-quality VR | NO |
| ARM | Armenia | Eastern Europe and central Asia | High-quality VR | NO |
| ATG | Antigua and Barbuda | Latin America and Caribbean | High-quality VR | NO |
| AUS | Australia | East Asia and Pacific | High-quality VR | NO |
| AUT | Austria | Western Europe | High-quality VR | NO |
| AZE | Azerbaijan | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| BDI | Burundi | Eastern and Southern Africa | High mortality model (HMM) | YES |
| BEL | Belgium | Western Europe | High-quality VR | NO |
| BEN | Benin | West and central Africa | High mortality model (HMM) | NO |
| BFA | Burkina Faso | West and central Africa | High mortality model (HMM) | YES |
| BGD | Bangladesh | South Asia | High mortality model (HMM) | NO |
| BGR | Bulgaria | Eastern Europe and central Asia | High-quality VR | NO |
| BHR | Bahrain | Middle East and North Africa | Low mortality model (LMM) | NO |
| BHS | Bahamas | Latin America and Caribbean | Low mortality model (LMM) | NO |
| BIH | Bosnia and Herzegovina | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| BLR | Belarus | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| BLZ | Belize | Latin America and Caribbean | Low mortality model (LMM) | NO |
| BOL | Bolivia (Plurinational State of) | Latin America and Caribbean | High mortality model (HMM) | NO |
| BRA | Brazil | Latin America and Caribbean | High-quality VR | NO |
| BRB | Barbados | Latin America and Caribbean | High-quality VR | NO |
| BRN | Brunei Darussalam | East Asia and Pacific | High-quality VR | NO |
| BTN | Bhutan | South Asia | High mortality model (HMM) | NO |
| BWA | Botswana | Eastern and Southern Africa | High mortality model (HMM) | NO |
| CAF | Central African Republic | West and central Africa | High mortality model (HMM) | YES |
| CAN | Canada | North America | High-quality VR | NO |
| CHE | Switzerland | Western Europe | High-quality VR | NO |
| CHL | Chile | Latin America and Caribbean | High-quality VR | NO |
| CHN | China | East Asia and Pacific | China DSP | NO |
| CIV | Côte d'Ivoire | West and central Africa | High mortality model (HMM) | NO |

| ISO3 | WHO name | Region | Model category | Fragile state |
|------|---|---------------------------------|----------------------------|---------------|
| CMR | Cameroon | West and central Africa | High mortality model (HMM) | YES |
| COD | Democratic Republic of the Congo | West and central Africa | High mortality model (HMM) | YES |
| COG | Congo | West and central Africa | High mortality model (HMM) | YES |
| COK | Cook Islands | East Asia and Pacific | Low mortality model (LMM) | NO |
| COL | Colombia | Latin America and Caribbean | High-quality VR | NO |
| COM | Comoros | Eastern and Southern Africa | High mortality model (HMM) | YES |
| CPV | Cabo Verde | West and central Africa | Low mortality model (LMM) | NO |
| CRI | Costa Rica | Latin America and Caribbean | High-quality VR | NO |
| CUB | Cuba | Latin America and Caribbean | High-quality VR | NO |
| CYP | Cyprus | Western Europe | High-quality VR | NO |
| CZE | Czechia | Western Europe | High-quality VR | NO |
| DEU | Germany | Western Europe | High-quality VR | NO |
| DJI | Djibouti | Eastern and Southern Africa | High mortality model (HMM) | NO |
| DMA | Dominica | Latin America and Caribbean | Low mortality model (LMM) | NO |
| DNK | Denmark | Western Europe | High-quality VR | NO |
| DOM | Dominican Republic | Latin America and Caribbean | Low mortality model (LMM) | NO |
| DZA | Algeria | Middle East and North Africa | Low mortality model (LMM) | NO |
| ECU | Ecuador | Latin America and Caribbean | High-quality VR | NO |
| EGY | Egypt | Middle East and North Africa | Low mortality model (LMM) | NO |
| ERI | Eritrea | Eastern and Southern Africa | High mortality model (HMM) | YES |
| ESP | Spain | Western Europe | High-quality VR | NO |
| EST | Estonia | Western Europe | High-quality VR | NO |
| ETH | Ethiopia | Eastern and Southern Africa | High mortality model (HMM) | NO |
| FIN | Finland | Western Europe | High-quality VR | NO |
| FJI | Fiji | East Asia and Pacific | High mortality model (HMM) | NO |
| FRA | France | Western Europe | High-quality VR | NO |
| FSM | Micronesia (Federated States of) | East Asia and Pacific | High mortality model (HMM) | YES |
| GAB | Gabon | West and central Africa | High mortality model (HMM) | NO |
| GBR | United Kingdom of Great Britain and Northern Ireland | Western Europe | High-quality VR | NO |
| GEO | Georgia | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| GHA | Ghana | West and central Africa | High mortality model (HMM) | NO |
| GIN | Guinea | West and central Africa | High mortality model (HMM) | NO |
| GMB | Gambia | West and central Africa | High mortality model (HMM) | YES |
| GNB | Guinea-Bissau | West and central Africa | High mortality model (HMM) | YES |
| GNQ | Equatorial Guinea | West and central Africa | High mortality model (HMM) | NO |
| GRC | Greece | Western Europe | High-quality VR | NO |
| GRD | Grenada | Latin America and Caribbean | High-quality VR | NO |
| GTM | Guatemala | Latin America and Caribbean | High mortality model (HMM) | NO |
| GUY | Guyana | Latin America and Caribbean | High-quality VR | NO |
| HND | Honduras | Latin America and Caribbean | Low mortality model (LMM) | NO |
| HRV | Croatia | Eastern Europe and central Asia | High-quality VR | NO |
| HTI | Haiti | Latin America and Caribbean | High mortality model (HMM) | YES |
| HUN | Hungary | Western Europe | High-quality VR | NO |
| IDN | Indonesia | East Asia and Pacific | High mortality model (HMM) | NO |
| IND | India | South Asia | High mortality model (HMM) | NO |
| IRL | Ireland | Western Europe | High-quality VR | NO |
| IRN | Iran (Islamic Republic of) | Middle East and North Africa | High mortality model (HMM) | NO |
| IRQ | Iraq | Middle East and North Africa | Low mortality model (LMM) | YES |
| ISL | Iceland | Western Europe | High-quality VR | NO |
| ISR | Israel | Middle East and North Africa | High-quality VR | NO |
| ITA | Italy | Western Europe | High-quality VR | NO |
| JAM | Jamaica | Latin America and Caribbean | Low mortality model (LMM) | NO |
| JOR | Jordan | Middle East and North Africa | Low mortality model (LMM) | NO |
| JPN | Japan | East Asia and Pacific | High-quality VR | NO |
| KAZ | Kazakhstan | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| KEN | Kenya | Eastern and Southern Africa | High mortality model (HMM) | NO |
| KGZ | Kyrgyzstan | Eastern Europe and central Asia | Low mortality model (LMM) | NO |

| ISO3 | WHO name | Region | Model category | Fragile state |
|------------|--|--------------------------------------|---|---------------|
| KHM | Cambodia | East Asia and Pacific | High mortality model (HMM) | NO |
| KIR | Kiribati | East Asia and Pacific | High mortality model (HMM) | YES |
| KNA | Saint Kitts and Nevis | Latin America and Caribbean | Low mortality model (LMM) | NO |
| KOR | Republic of Korea | East Asia and Pacific | High-quality VR | NO |
| KWT | Kuwait | Middle East and North Africa | Low mortality model (LMM) | NO |
| LAO | Lao People's Democratic Republic | East Asia and Pacific | High mortality model (HMM) | YES |
| LBN | Lebanon | Middle East and North Africa | Low mortality model (LMM) | YES |
| LBR | Liberia | West and central Africa | High mortality model (HMM) | YES |
| LBY | Libya | Middle East and North Africa | Low mortality model (LMM) | YES |
| LCA | Saint Lucia | Latin America and Caribbean | High-quality VR | NO |
| LKA | Sri Lanka | South Asia | Low mortality model (LMM) | NO |
| LSO | Lesotho | Eastern and Southern Africa | High mortality model (HMM) | NO |
| LTU | Lithuania | Western Europe | High-quality VR | NO |
| LUX | Luxembourg | Western Europe | High-quality VR | NO |
| LVA | Latvia | Western Europe | High-quality VR | NO |
| MAR | Morocco | Middle East and North Africa | Low mortality model (LMM) | NO |
| MCO | Monaco | Western Europe | Low mortality model (LMM) | NO |
| MDA | Republic of Moldova | Eastern Europe and central Asia | High-quality VR | NO |
| MDG | Madagascar | Eastern and Southern Africa | High mortality model (HMM) | NO |
| MDV | Maldives | South Asia | Low mortality model (LMM) | NO |
| MEX | Mexico | Latin America and Caribbean | High-quality VR | NO |
| MHL | Marshall Islands | East Asia and Pacific | High mortality model (HMM) | YES |
| MKD | Republic of North Macedonia | Eastern Europe and central Asia | High-quality VR | NO |
| MLI | Mali | West and central Africa | High mortality model (HMM) | YES |
| MLT | Malta | Western Europe | High-quality VR | NO |
| MMR | Myanmar | East Asia and Pacific | High mortality model (HMM) | YES |
| MNE | Montenegro | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| MNG | Mongolia | East Asia and Pacific | High mortality model (HMM) | NO |
| MOZ | Mozambique | Eastern and Southern Africa | High mortality model (HMM) | YES |
| MRT | Mauritania | West and central Africa | High mortality model (HMM) | NO |
| MUS | Mauritius | Eastern and Southern Africa | High-quality VR | NO |
| MWI | Malawi | Eastern and Southern Africa | High mortality model (HMM) | NO |
| MYS | Malaysia | East Asia and Pacific | Low mortality model (LMM) | NO |
| NAM | Namibia | Eastern and Southern Africa | High mortality model (HMM) | NO |
| NER | Niger | West and central Africa | High mortality model (HMM) | YES |
| NGA | Nigeria | West and central Africa | High mortality model (HMM) | YES |
| NIC | Nicaragua | Latin America and Caribbean | High-quality VR | NO |
| NLD | Netherlands | Western Europe | High-quality VR | NO |
| NOR | Norway | Western Europe | High-quality VR | NO |
| NPL | Nepal | South Asia | High mortality model (HMM) | NO |
| NRU | Nauru | East Asia and Pacific | High mortality model (HMM) | NO |
| NUI | Niue | East Asia and Pacific | High mortality model (HMM) | NO |
| NZL | New Zealand | East Asia and Pacific | High-quality VR | NO |
| OMN | Oman | Middle East and North Africa | Low mortality model (LMM) | NO |
| PAK | Pakistan | South Asia | High mortality model (HMM) | NO |
| PAN | Panama | Latin America and Caribbean | High-quality VR | NO |
| PER | Peru | Latin America and Caribbean | High-quality VR | NO |
| PHL | Philippines | East Asia and Pacific | High-quality VR | NO |
| PLW | Palau | East Asia and Pacific | High mortality model (HMM) | NO |
| PNG | Papua New Guinea | East Asia and Pacific | High mortality model (HMM) | YES |
| POL PRK | Poland Democratic People's Republic | Western Europe East Asia and Pacific | High-quality VR High mortality model (HMM) | NO NO |
| | of Korea | | , , , | |
| PRT | Portugal | Western Europe | High-quality VR | NO |
| PRY | Paraguay | Latin America and Caribbean | High-quality VR | NO |
| PSE | West Bank and Gaza Strip | Middle East and North Africa | Low mortality model (LMM) | YES |
| QAT | Qatar | Middle East and North Africa | Low mortality model (LMM) | NO |
| ROU | Romania | Eastern Europe and central Asia | High-quality VR | NO |
| RUS | Russian Federation | Eastern Europe and central Asia | Low mortality model (LMM) | NO |

| ISO3 | WHO name | Region | Model category | Fragile state |
|------|---------------------------------------|---------------------------------|----------------------------|---------------|
| RWA | Rwanda | Eastern and Southern Africa | High mortality model (HMM) | NO |
| SAU | Saudi Arabia | Middle East and North Africa | Low mortality model (LMM) | NO |
| SDN | Sudan | Eastern and Southern Africa | High mortality model (HMM) | YES |
| SEN | Senegal | West and central Africa | High mortality model (HMM) | NO |
| SGP | Singapore | East Asia and Pacific | High-quality VR | NO |
| SLB | Solomon Islands | East Asia and Pacific | High mortality model (HMM) | YES |
| SLE | Sierra Leone | West and central Africa | High mortality model (HMM) | NO |
| SLV | El Salvador | Latin America and Caribbean | High-quality VR | NO |
| SMR | San Marino | Western Europe | Low mortality model (LMM) | NO |
| SOM | Somalia | Eastern and Southern Africa | High mortality model (HMM) | YES |
| SRB | Serbia | Eastern Europe and central Asia | High-quality VR | NO |
| SSD | South Sudan | Eastern and Southern Africa | High mortality model (HMM) | YES |
| STP | Sao Tome and Principe | West and central Africa | High mortality model (HMM) | NO |
| SUR | Suriname | Latin America and Caribbean | Low mortality model (LMM) | NO |
| SVK | Slovakia | Western Europe | High-quality VR | NO |
| SVN | Slovenia | Western Europe | High-quality VR | NO |
| SWE | Sweden | Western Europe | High-quality VR | NO |
| SWZ | Eswatini | Eastern and Southern Africa | High mortality model (HMM) | NO |
| SYC | Seychelles | Eastern and Southern Africa | Low mortality model (LMM) | NO |
| SYR | Syrian Arab Republic | Middle East and North Africa | Low mortality model (LMM) | YES |
| TCD | Chad | West and central Africa | High mortality model (HMM) | YES |
| TGO | Togo | West and central Africa | High mortality model (HMM) | NO |
| THA | Thailand | East Asia and Pacific | High mortality model (HMM) | NO |
| TJK | Tajikistan | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| TKM | Turkmenistan | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| TLS | Timor-Leste | East Asia and Pacific | High mortality model (HMM) | YES |
| TON | Tonga | East Asia and Pacific | Low mortality model (LMM) | NO |
| TTO | Trinidad and Tobago | Latin America and Caribbean | Low mortality model (LMM) | NO |
| TUN | Tunisia | Middle East and North Africa | Low mortality model (LMM) | NO |
| TUR | Turkey | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| TUV | Tuvalu | East Asia and Pacific | High mortality model (HMM) | YES |
| TZA | United Republic of Tanzania | Eastern and Southern Africa | High mortality model (HMM) | NO |
| UGA | Uganda | Eastern and Southern Africa | High mortality model (HMM) | NO |
| UKR | Ukraine | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| URY | Uruguay | Latin America and Caribbean | High-quality VR | NO |
| USA | United States of America | North America | High-quality VR | NO |
| UZB | Uzbekistan | Eastern Europe and central Asia | Low mortality model (LMM) | NO |
| VCT | Saint Vincent and the Grenadines | Latin America and Caribbean | High-quality VR | NO |
| VEN | Venezuela (Bolivarian Republic of) | Latin America and Caribbean | High-quality VR | YES |
| VNM | Viet Nam | East Asia and Pacific | Low mortality model (LMM) | NO |
| VUT | Vanuatu | East Asia and Pacific | High mortality model (HMM) | NO |
| WSM | Samoa | East Asia and Pacific | Low mortality model (LMM) | NO |
| YEM | Yemen | Middle East and North Africa | High mortality model (HMM) | YES |
| ZAF | South Africa | Eastern and Southern Africa | High mortality model (HMM) | NO |
| ZMB | Zambia | Eastern and Southern Africa | High mortality model (HMM) | NO |
| ZWE | Zimbabwe | Eastern and Southern Africa | High mortality model (HMM) | YES |

Webappendix 2. Cause categorization and ICD codes

Specific causes of death (COD) that made up at least 3% of global deaths in 2016 among any of the adolescent 5-year-age-and-sex groups according to the existing estimates^{4,5} were considered for modeling. The final causes were influenced by model stability, which was driven by the frequency and magnitude of the cause fractions in the empirical data. Remaining causes were grouped into the respective "other" categories (Other communicable, maternal, perinatal and nutritional conditions – Other CMPN; Other non-communicable diseases – Other NCD; and Other injuries).

Table S2. Cause list and the ICD code mapping

| Cause name | ICD-10 |
|---|---|
| Communicable, maternal, perinatal, and nutritional conditions | A00-B99, D50-D53, D64·9, E00-E02, E40-E46, E50-E68, G00, G03-G04, H65-H66, J00-J22, N70-N73, O00-O99, P00-P96 (except P23, P37·3, P37·4), U04 |
| HIV/AIDS | B20-B24 |
| Diarrheal | A00, A01, A03, A04, A06-A09 |
| Measles | B05 |
| Malaria | B50-B54 |
| Lower Respiratory Infections | J09-J22, P23, U04 |
| Tuberculosis | A15-A19, B90 |
| Maternal causes | O00-O99 |
| Other CMPN | Remainder of communicable, maternal, perinatal, and nutritional conditions |
| Non-communicable diseases | C00-C97, D00-D48, D55-D89 (except D64.9), E03-E07, E10-E34, E65-E88, F01-F99, G06-G98, H00-H61, H68-H93, I00-I99, J30-J98, K00-K92, L00-L98, M00-M99, N00-N64, N75-N98, Q00-Q99 |
| Congenital anomalies | Q00-Q99 |
| Neoplasms | C00-D48 |
| Cardiovascular disease | 100-199 |
| Diseases of the digestive system | K20-K92 |
| Other NCD | Remainder of non-communicable diseases |
| Injuries | V01-Y09, Y35-Y36, Y40-Y86, Y88-Y89, Y871 |
| Road traffic injuries | V01-V04, V06, V09-V80, V87, V89, V99 |
| Drownings | W65-W74 |
| Natural disaster | X30-X39 |
| Interpersonal violence | X85-Y09, Y871 |
| Collective violence: legal intervention | Y35 |
| Collective violence: war | Y36 |
| Self-harm | X60-X84, Y871 |
| Other injuries | Remainder of injuries |
| Ill-defined | R00-R99, Y10-Y34, Y872 |

Webappendix 3. Model input data procurement and preparation

Webappendix 3.1 Covariates and their preparation

Each covariate had at least 200 empirical country data points between 1980 and 2017, and covariates with high age-sex resolution were prioritized. Covariates were matched to the study population using the following hierarchy: location, year, age, and sex.

For covariates, empirical data was first taken directly from their source without adjustments. A complete time-series for each country was then generated using linear interpolation between existing empirical data points, extrapolation assuming a flat trend for years preceding or succeeding the last available empirical data points, and imputation based on region and country's lag distributed GDP where there was no empirical data. These time series were used for country-years in the input database that did not have subnational covariate data. A smoothed times series was also generated using a 7-year average for model prediction.

Table S3.1. List of Covariates

| Covariate | Description | Source | Included in final model |
|--|--|--|--|
| Alcohol consumption | Alcohol consumption per capita (in liters of pure alcohol) | World Health Organization Global Health Observatory (WHO GHO) | 10-14 HMM 10-14 LMM 15-19 Males HMM 15-19 Males LMM 15-19 Females HMM 15-19 Females LMM |
| Depression | Prevalence of Depressive disorders (%) | Institute for Health Metrics and Evaluation Global Burden of Disease | 10-14 HMM 15-19 Males HMM 15-19 Males LMM 15-19 Females HMM |
| ORS | Oral Rehydration Salts (%) | USAID Demographic Health Surveys (DHS) and UNICEF Multiple Indicator Cluster Surveys (MICS) | 10-14 HMM |
| DTP3 vaccine | Diphtheria-tetanus-pertussis vaccine | DHS and MICS | 5-9 HMM 10-14 HMM |
| Institutional delivery | Place of delivery: Health facility | DHS | 15-19 Females HMM 15-19 Females LMM |
| LBW | Low birth weight | The World Bank | 5-9 HMM |
| Adolescent birth rate | Age-specific fertility rates (births per 1,000 women) | United Nations Population Division World Population Prospects (UNDP WPP) | 15-19 Females LMM |
| Age at first sexual intercourse 15 | Percentage of people who had first sexual intercourse by exact age 15) | DHS | 10-14 HMM 10-14 LMM 15-19 Males LMM 15-19 Females HMM |
| Marriage | Mean age at marriage | UNDP World Marriage Data | 15-19 Males HMM 15-19 Males LMM 15-19 Females LMM |
| Early childbearing | Average age of mothers at the birth of their children | UN WPP | 15-19 Females HMM 15-19 Females LMM |

| Covariate | Description | Source | Included in final model |
|---|--|--|---|
| Unmet need for family planning | Women unmet need for family planning (%) | UNPD World Contraceptive Use | 15-19 Females HMM |
| Corruption | Perceived levels of public sector corruption according to experts and businesspeople | Transparency International Corruption Perceptions Index | 5-9 HMM 5-9 LMM 10-14 HMM 10-14 LMM 15-19 Males HMM 15-19 Males LMM |
| Mean years of schooling | Average Years of Total Schooling | Barro-Lee Educational Attainment Dataset | 5-9 HMM 5-9 LMM 10-14 LMM 15-19 Males LMM 15-19 Females LMM |
| Labor force participation | Labor force participation rate (%) | The World Bank | 15-19 Males HMM |
| Unemployment | unemployment % of total labor force | The World Bank | 15-19 Males HMM |
| Youth NEET | Youth NEET (not in employment, education, or training) rate (%) | International Labour Organization | 5-9 HMM 5-9 LMM 10-14 LMM 15-19 Males LMM 15-19 Females LMM |
| Literacy | Youth literacy rate, population 15-24 years | United Nations Educational, Scientific and Cultural Organization Institute for Statistics | 15-19 Males HMM 15-19 Females HMM |
| People living in lowest wealth quintile | Population in the lowest wealth quintile (%) | DHS | 5-9 HMM 5-9 LMM 10-14 HMM 10-14 LMM 15-19 Males HMM 15-19 Females HMM 15-19 Females LMM |
| Height | Mean height at age 18 (cm) | NCD Risk Factor Collaboration (NCD RisC) | 5-9 HMM |
| Underweight | Prevalence of WAZ < 2 SD | Stevens <i>et al.</i> (2012) ⁶ | 5-9 LMM 10-14 LMM |
| Obese | Obese (BMI>+2 standard deviation above the median) | NCD RisC | 5-9 LMM 10-14 LMM 15-19 Males LMM 15-19 Females LMM |
| Thinness | Thinness (BMI<-2 standard deviation below the median) | NCD RisC | 5-9 HMM 5-9 LMM 10-14 HMM 10-14 LMM 15-19 Males LMM 15-19 Females HMM 15-19 Females LMM |
| PfPR | P. falciparum parasite rate | Oxford Malaria Atlas Project | 5-9 HMM 10-14 HMM |

| Covariate | Description | Source | Included in final model |
|-----------------------|--|--------------------------------------|---|
| Air pollution | PM 2.5 aerosol mass | NASA Merra-2 ⁷ | 5-9 HMM 5-9 LMM 10-14 HMM 10-14 LMM 15-19 Males LMM 15-19 Females LMM |
| Urban | Urban population % | UNDP World Urbanization Prospects | 5-9 HMM 5-9 LMM 10-14 HMM 10-14 LMM 15-19 Males HMM 15-19 Females HMM 15-19 Females LMM |
| GINI | GINI Index | The World Bank | 5-9 HMM 10-14 HMM 15-19 Males HMM 15-19 Females HMM |
| Population under 5 | Proportion of population aged 0-4 years old | UNDP WPP | 5-9 LMM |
| Population male 15-29 | Proportion of population aged 15–30 years old and male | UNDP WPP | 15-19 Males LMM |
| MR5to19 | 5-19 Mortality rate | UN-IGME | 5-9 HMM 10-14 HMM 15-19 Females HMM 15-19 Females LMM |
| Year | | | 5-9 LMM 10-14 LMM 15-19 Males HMM 15-19 Males LMM |

Webappendix 3.2 COD model inputs preparation

Systematic review for verbal autopsy studies

We conducted a systematic review for verbal autopsy studies published between January 1, 1980, and December 31, 2017 to be used as model inputs. We used search terms related to COD, ages 5-19, and HMM countries in major search engines covering global health and epidemiology journals (Yeung D, Feng Y, Hong J, *et al.*; unpublished data). Articles were screened with pre-set inclusion and exclusion criteria and abstracted by two independent researchers using DistillerSR software.⁸ We started with 55,471 articles and eventually included 62 in the final analysis.

Search items for systematic review

We searched on Pubmed, Scopus, Embase, Web of Science, Global Health Index Medicus, Global Health OVID, IndMed, PAHO, Popline, and Cochrane for studies published between January 1, 1980 and December 31, 2017, using the following search terms:

```
(("Adolescent" OR "adolescents" OR "adolescence" OR "teen" OR "teens" OR "teenager" OR "teenagers" OR "youth" OR "youths" OR "young adult" OR "young adults" OR "young person" OR "young people" OR "preteen" OR "preteens") OR

(("child" OR "children") AND

("6 years" OR "7 years" OR "8 years" OR "9 years" OR "10 years" OR "11 years" OR "12 years" OR "13 years" OR "14 years" OR "15 years" OR "school age" OR "age 6" OR "ages 6" OR "age 7" OR "ages 7" OR "ages 8" OR "ages 8" OR "age 9" OR "ages 9" OR "age 10" OR "ages 10" OR "age 11" OR "ages 11" OR "ages 12" OR "ages 12" OR "age 13" OR "ages 13" OR "ages 14" OR "ages 15" OR "ages 15"))) AND
```

```
(("Cause of death" OR "causes of death") OR
```

(("cause" OR "causes" OR "autopsy" OR "autopsies" OR "disease burden" OR "survey" OR "surveys" OR "surveillance" OR "register" OR "registers" OR "registration" OR "vital statistics" OR "report" OR "reports") AND

("Mortality" OR "Mortalities" OR "fatal" OR "fatality" OR "fatalities" OR "death" OR "deaths"))) AND

("Afghanistan" OR "Algeria" OR "Angola" OR "Azerbaijan" OR "Bangladesh" OR "Benin" OR "Bhutan" OR "Bolivia" OR "Botswana" OR "Burkina Faso" OR "Burundi" OR "Cambodia" OR "Cameroon" OR "Central African Republic" OR "Chad" OR "China" OR "Comoros" OR "Congo" OR "Cote d'Ivoire" OR "Democratic People's Republic of Korea" OR "Congo" OR "Djibouti" OR "Dominican Republic" OR "Equatorial Guinea" OR "Eritrea" OR "Ethiopia" OR "Gabon" OR "Gambia" OR "Ghana" OR "Guatemala" OR "Guinea" OR "Guinea-Bissau" OR "Haiti" OR "India" OR "Indonesia" OR "Iran" OR "Iraq" OR "Kazakhstan" OR "Kenya" OR "Kiribati" OR "Kyrgyzstan" OR "Laos" OR "Lesotho" OR "Liberia" OR "Madagascar" OR "Malawi" OR "Mali" OR "Marshall Islands" OR "Mauritania" OR "Micronesia" OR "Mongolia" OR "Morocco" OR "Mozambique" OR "Myanmar" OR "Namibia" OR "Nauru" OR "Nepal" OR "Niger" OR "Nigeria" OR "Pakistan" OR "Papua New Guinea" OR "Philippines" OR "Rwanda" OR "Sao Tome and Principe" OR "Senegal" OR "Sierra Leone" OR "Solomon Islands" OR "Somalia" OR "South Africa" OR "South Sudan" OR "Sudan" OR "Swaziland" OR "Tajikistan" OR "Timor-Leste" OR "Togo" OR "Turkmenistan" OR "Uganda" OR "Tanzania" OR "Uzbekistan" OR "Yemen" OR "Zambia" OR "Zimbabwe" OR "developing country" OR "developing countries" OR "developing nation" OR "developing nations" OR "developing population" OR "developing populations" OR "developing world" OR "less developed country" OR "less developed countries" OR "less developed nation" OR "less developed nations" OR "less developed population" OR "less developed populations" OR "less developed world" OR "lesser developed country" OR "lesser developed countries" OR "lesser developed nation" OR "lesser developed nations" OR "lesser developed population" OR "lesser developed populations" OR "lesser developed world" OR "under developed country" OR "under developed countries" OR "under developed nation" OR "under developed nations" OR "under developed population" OR "under developed populations" OR "under developed world" OR "underdeveloped country" OR "underdeveloped countries" OR "underdeveloped nation" OR "underdeveloped nations" OR "underdeveloped population" OR "underdeveloped populations" OR "underdeveloped world" OR "middle income country" OR "middle income countries" OR "middle income nation" OR "middle income nations" OR "middle income population" OR "middle income populations" OR "low income country" OR "low income countries" OR "low income nation" OR "low income nations" OR "low income population" OR "low income populations" OR "lower income country" OR "lower income countries" OR "lower income nation" OR "lower income nations" OR "lower income population" OR "lower income populations" OR "underserved country" OR "underserved countries" OR "underserved nation" OR "underserved nations" OR "underserved population" OR "underserved populations" OR "underserved world" OR "under served country" OR "under served countries" OR "under served nation" OR "under served nations" OR "under served population" OR "under served populations" OR "under served world" OR "deprived country" OR "deprived countries" OR "deprived nation" OR "deprived nations" OR "deprived population" OR "deprived populations" OR "deprived world" OR "poor country" OR "poor countries" OR "poor nation" OR "poor nations" OR "poor population" OR "poor populations" OR "poor world" OR "poorer country" OR "poorer countries" OR "poorer nation" OR "poorer nations" OR "poorer population" OR "poorer populations" OR "poorer world" OR "developing economy" OR "developing economies" OR "less developed economy" OR "less developed economies" OR "lesser developed economy" OR "lesser developed economies" OR "under developed economy" OR "under developed economies" OR "underdeveloped economy" OR "underdeveloped economies" OR "middle income economy" OR "middle income economies" OR "low income economy" OR "low income economies" OR "lower income economy" OR "lower income economies" OR "low gdp" OR "low gnp" OR "low gross domestic" OR "low gross national" OR "lower gdp" OR "lower gnp" OR "lower gross domestic" OR "lower gross national" OR "lmic" OR "lmics" OR "third world" OR "lami country" OR "lami countries" OR "transitional country" OR "transitional countries" OR "Africa" OR "Africa South of the Sahara" OR "Africa, Central" OR "Africa, Eastern" OR "Africa, Southern" OR "Africa, Western" OR "Africa, Northern" OR "Caribbean Region" OR "West Indies" OR "Central America" OR "Latin America" OR "South America" OR "Asia, Central" OR "Asia, Northern" OR "Asia, southeastern" OR "Asia, western" OR "middle east" OR "Asia" OR "far east" OR "Transcaucasia" OR "USSR" OR "Atlantic Islands" OR "Indian Ocean Islands" OR "Pacific Islands" OR "Micronesia" OR "Melanesia" OR "province" OR "provinces" OR "district" OR "districts" OR "prefecture" OR "prefectures" OR "county" OR "counties" OR "municipality" OR "municipalities")

Exclusion criteria for systematic review

The following criteria were used to screen articles captured in the systematic review. Articles were excluded if they fulfilled any of the following:

- 1. Did not disaggregated data between 5-19-year-olds.
- 2. Aggregated data beyond 24-year-olds.
- 3. Did not present cause of death data.
- 4. Included less than two specific causes of death.
- 5. Was not conducted in a high-mortality country without high-quality vital registration data.
- 6. Was not conducted using standardized verbal autopsy methods.
- 7. Had more than 25% of deaths with undefined causes.
- 8. Was not conducted in a general population.
- 9. Completed surveillance before 1980.
- 10. Did not have a reference period that was 12 months (±1 month) or did not have a study duration of more than 24 months.
- 11. Did not present primary data.

Collapsing into study input data points

In both LMM and HMM, datapoints were collapsed hierarchically by year, sex, and/or age, to contain at least 15 deaths and reduce idiosyncratic errors, and retained if they included at least two causes. To limit the influence of extremely large but less informative data points, in the HMM studies were dropped if they included more than 5,000 total deaths or had 25% or more deaths categorized as "undetermined". As a result, 12 data points were dropped among 5-9 (4.9%), 9 among 10-14 (3.6%), and 8 among 15-19 (2.9%). Moreover, data points with more than 1,000 deaths in which one cause represented more than 50% of total deaths were also dropped, but this only applied to 4 datapoints for 15-19 males with large fractions of interpersonal violence.


VR data used in the HMM

To enhance model stability, we included 30 high-quality VR data points in the HMM input. In particular, we identified countries with high-quality VR data in which the all-cause mortality rate between ages 5 and 20 ($_{15}q_5$) was above 10 per 1,000 population (threshold between LMM and HMM countries) at some point between 2000-2019. Next, for each of these countries, we selected the last year with empirical high-quality VR data in which $_{15}q_5 \ge 10$. The table below summarizes the high-quality VR data points included in the HMM input.

Table S3.2. Vital registration data used in high-mortality model

| ISO3 | Country name | Year | ₁₅ q ₅ | Deaths 5-19 | Age-sex group |
|------|--------------|------|-------------------------------------|-------------|------------------------|
| COL | Colombia | 2003 | 10.36 | 8,582 | All except 15-19 males |
| ECU | Ecuador | 2003 | 10.04 | 2,850 | |
| GUY | Guyana | 2014 | 11.28 | 185 | |
| NIC | Nicaragua | 2006 | 10.08 | 1,295 | A 11 |
| PER | Peru | 2002 | 10.01 | 5,933 | All age-sex groups |
| PRY | Paraguay | 2004 | 10.04 | 1,335 | |
| SLV | El Salvador | 2015 | 11.47 | 1,518 | |
| VEN | Venezuela | 2014 | 13.58 | 7,509 | All except 15-19 males |

Webappendix 3.3 Input data map



Note: The Chinese DSP comprises 5,648 site-years for ages 5-19, not shown in the map.

Webappendix 4. Additional details of modeling and estimation

Webappendix 4.1 The Bayesian LASSO

A thorough description of the Bayesian LASSO model used here can be found elsewhere. A brief overview is provided in the following.

Suppose there exist C mutually exclusive causes of death, and that we have a sample of N_S deaths from a given study s, each of which is (correctly) classified into one and only one of the C categories. If we denote the distribution of true COD in the sample as $T_{1,s}, T_{2,s}, ..., T_{C,s}$ and if the sample is random, we can assume that these observations come from a multinomial distribution,

$$\begin{bmatrix} T_{1,S} \\ T_{2,S} \\ \vdots \\ T_{C,S} \end{bmatrix} \sim \text{Multinomial} \begin{pmatrix} N_S, \begin{bmatrix} P_{1,S} \\ P_{2,S} \\ \vdots \\ P_{C,S} \end{bmatrix} \end{pmatrix},$$

where $P_{c,s}$ refers to the probability that a death is due to cause c in the population in which study s is conducted.

Suppose the probabilities $P_{c,s}$ can be predicted by the values of a set of K explanatory variables $X_{1,s}, X_{2,s}, ..., X_{K,s}$. In a multinomial regression framework, we assume that the logarithm of the odds of each cause of death relative to a reference cause are linearly dependent on these explanatory variables. This is expressed as a system of C-1 linear equations corresponding to each cause of death (excluding the reference category $P_{1,s}$),

$$\log(P_{2,s}/P_{1,s}) = \beta_{2,0} + \beta_{2,1}X_{1,s} + \beta_{2,2}X_{2,s} + \dots + \beta_{2,K}X_{K,s}$$

$$\log(P_{3,s}/P_{1,s}) = \beta_{3,0} + \beta_{3,1}X_{1,s} + \beta_{3,2}X_{2,s} + \dots + \beta_{3,K}X_{K,s}$$

$$\vdots$$

$$\log(P_{C,s}/P_{1,s}) = \beta_{C,0} + \beta_{C,1}X_{1,s} + \beta_{C,2}X_{2,s} + \dots + \beta_{C,K}X_{K,s}$$

Note that the β -coefficients (including the intercepts) do not have the study subindex s. This is a fixed-effects model that assumes the associations of the explanatory variables with the causes of death are constant across all studies. We relax this assumption by adding study-specific normally distributed random effects to the intercepts, with mean 0 and cause-specific standard deviations. These standard deviations have uniformly distributed priors bounded between 0 and parameter b.

We implemented LASSO covariate selection by penalizing large β -coefficients in a subset of the fixed-effect parameters that could potentially result in overfitting the data. We did this by imposing a double exponential (also referred to as Laplace) prior distribution on them in the model specification.¹⁰ This shrinks the magnitude of the parameters without completely reducing them to zero, and has the additional advantage of stabilizing the model if convergence is slow or difficult. The intercepts and any β -coefficient we did not want to be constrained in the LASSO were given non-informative normally distributed priors. The remaining β -coefficients had a Laplace prior with mean 0 and precision $\lambda > 0$, the penalty imposed by the LASSO method. We used out-of-sample cross-validation to select the optimal λ and b parameters (see Webappendix 9).

Once the model has estimated the β -coefficients and study-specific random effects, we estimated the expected distribution of true causes of death in any country for which we have covariate data as

$$P_{c,s} = \frac{\exp[U_{c,s} + \boldsymbol{\beta}_c \times \boldsymbol{X}_s]}{1 + \exp[U_{2,s} + \boldsymbol{\beta}_2 \times \boldsymbol{X}_s] + \dots + \exp[U_{c,s} + \beta_c \times \boldsymbol{X}_s]},$$

where $U_{c,s}$ denotes the cause- and study-specific random effect, β_c is a vector with β -coefficients for cause c, and X_s is the vector of covariates in study s.

The base category

For each age-sex group and model, selection of the base cause was guided by its global burden and input data availability. Specifically, we selected the base category by identifying the cause with the largest number of deaths in the input database.

Table S4.1. Base category for each age-sex group and model in the Bayesian LASSO

| Model | Age-sex group | Base category |
|----------------------------|---------------|------------------------------|
| | 5-9 years | N1 |
| 11/11/11/11 | 10-14 years | Neoplasms |
| Low mortality model (LMM) | 15-19 females | D 14 CC ' ' ' |
| | 15-19 males | Road traffic injuries |
| | 5-9 years | Diarrheal |
| II' 1 4 1'4 1 1 (IDAA) | 10-14 years | Lower respiratory infections |
| High mortality model (HMM) | 15-19 females | Self-harm |
| | 15-19 males | Road traffic injuries |

Webappendix 4.2 Estimation of the sex-specific deaths and rates for 15-19

Country-level estimates on all-cause mortality (envelopes) were borrowed from the United Nations Inter-agency Group for Child Mortality Estimation (UN-IGME).² For the period 1990-2019 and ages 5 to 24, UN-IGME provides annual estimates on the number of deaths and mortality rates for 195 countries in 5- and 10-year age groups.¹¹

However, UN-IGME has yet to publish sex-specific mortality envelopes for ages 5+. We used sex-specific life tables from the United Nations (UN)¹² to obtain all-cause sex-specific mortality rates and number of deaths for the 15-19 age group as follows:

- 1. For each country-year available, we recovered from the UN life tables the central death rates from 15 to 19 years for both sexes together $(_5m_{15})$, for males $(_5m_{15}^M)$ and females $(_5m_{15}^F)$. Using these rates, for all country-years we calculated a male ratio $R^M = _5m_{15}^M/_5m_{15}$ and a female ratio $R^F = _5m_{15}^F/_5m_{15}$.
- 2. We transformed the UN-IGME probabilities of dying between ages 15 and 19 ($_5q_{15}$) into central death rates by applying the formula $_5m_{15} = _5q_{15}/(5 \times (1000 _5q_{15} \times 0.5))$, which assumes that deaths are equally distributed within each of the corresponding age intervals. Note

- that UN-IGME reports probabilities of dying, even though they refer to them as 'mortality rates',² which justifies this intermediate step.
- 3. Next, we applied the ratios R^M and R^F calculated from the UN life tables to the estimated central death rates from UN-IGME ($_5m_{15}$), obtaining the sex-specific death rates $_5m_{15}^M=R^M\times _5m_{15}$ and $_5m_{15}^F = R^F \times _5m_{15}$.

 4. Finally, we back transformed these rates into sex-specific probabilities of dying, given by
- $_{5}q_{15}^{M} = 5000 \times {}_{5}m_{15}^{M}/(1 + 2.5 \times {}_{5}m_{15}^{M}) \text{ and } _{5}q_{15}^{F} = 5000 \times {}_{5}m_{15}^{F}/(1 + 2.5 \times {}_{5}m_{15}^{F}).$

Similarly, we used the population shares by age and sex from UN World Population Prospects (UN-WPP)¹² to calculate the sex-specific number of deaths in the 15-19 age group.

- 5. For each country-year, we divided the reported number of deaths $({}_5D_{15})$ from UN-IGME by the estimated death rates $_5m_{15}$ defined above, obtaining the population at risk for both sexes $_5P_{15} = _5D_{15}/_5m_{15}.$
- 6. Let $Prop^{M}$ and $Prop^{F}$ denote the country- and year-specific shares by sex from UN-WPP for the 15-19 age group. We calculated the sex-specific population at risk for each country-year as $_5P_{15}^M = Prop^M \times _5P_{15}$ and $_5P_{15}^F = Prop^F \times _5P_{15}$.

 7. Finally, we estimated the sex-specific number of deaths for the 15-19 age group multiplying the
- sex-specific populations at risk by the sex-specific death rates from UN-IGME estimated above: $_{5}D_{1}^{M} = {}_{5}P_{15}^{M} \times {}_{5}m_{15}^{M}$ and $_{5}D_{15}^{F} = {}_{5}P_{15}^{F} \times {}_{5}m_{15}^{F}$.

Webappendix 4.3 Point estimates and uncertainty

We run 10,000 iterations of the eight Bayesian models (LMM and HMM in each of the four age-sex groups) in four parallel chains. To assess convergence, we used an initial burn-in sequence of 4,000 and a thinning interval of 20 and calculated potential scale reduction factor. ¹³ Hence, for each of the model parameters—and for each of the eight models—we got 1,204 sets of estimates after burn-in. We used these sets to calculate mean values of the multinomial regression parameters and obtain point estimates of the cause-specific mortality fractions, mortality rates and death counts. To estimate uncertainty, we used the 1,204 sets of multinomial regression parameters from the Bayesian model to obtain 1,204 sets of mortality estimates for each country-year and calculate uncertainty intervals. More specifically, for each draw we

- 1. Calculated mortality fractions for all countries in the period 2000-2019;
- 2. Randomly drew all-cause mortality estimates from the posterior distribution of the mortality envelopes;²
- 3. Incorporated single-cause estimates. For each country-year, values of the single-cause estimates were drawn from the corresponding uncertainty intervals, with the following assumptions:
 - For HIV/AIDS, we assumed data were normally distributed but truncated at 0, to avoid negative values. We used the point estimates as the means an estimated the standard deviations by dividing the range of the corresponding 95% uncertainty intervals by 3.92.
 - For TB and measles, the upper bounds of the corresponding 95% uncertainty intervals tended to be large, indicating skewed distributions with long upper tails. To account for that, we drew values from log-normal distributions with matching means and standard deviations. Let a and b denote the lower and upper bounds of the 95% uncertainty intervals, respectively, and m the point estimate. We defined s = (b - a)/3.92, and used standard formulae to obtain the usual log-normal parameters mean μ and variance σ^2 , given by

$$\mu = \log\left(\frac{m^2}{\sqrt{s^2 + m^2}}\right)$$
 and $\sigma^2 = \log\left(1 + \frac{s^2}{m^2}\right)$.

Webappendix 4.4 Transparency and replicability

We carried out our analyses using the open-source statistical software R¹⁴ and Bayesian modelling was implemented in JAGS¹⁵ with wrapper functions from the R2jags package.¹⁶ The source code, primary inputs and cause of death data collected and estimated are publicly available for research purposes from the GitHub repository https://github.com/panchoVG/Mort5to19.

Webappendix 5. Modeling and estimation strategies

| | High-quality VR (n=67) | Low mortality model (15q5<10 in 2010, n=52) | High mortality model (15q5≥10 in 2010, n=76) | | | | |
|-------------------|---|--|--|--|--|--|--|
| Data inputs | High quality VR data | High quality VR data without interpolation/extrapolation | Primarily VA data | | | | |
| Model building | VR data used as is or with minor adjustments | Bayesian multinomial-logistic model with country random effects Covariate selection: LASSO through cross-validation | | | | | |
| Outputs | CSMFs: directly from VR data | 2.70 | MFs: covariates by country and year | | | | |
| 8 | # of deaths & risk by cause: apply CSMFs to UN-IGME neonatal deaths & live births by country- | | | | | | |
| 5 | Draw from a multinomial distribution | AND THE PROPERTY OF THE PROPER | ibutions of Bayesian LASSO random effect estimates | | | | |

VR: Vital Registration; VA: Verbal Autopsy; LASSO: Least Absolute Shrinkage and Selection Operator; CSMF: Cause-Specific Mortality Fraction; UN-IGME: United Nations Inter-agency Group for Child Mortality Estimation


Webappendix 6. Additional details on single cause estimates

Webappendix 6.1 Splitting measles into endemic and epidemic

Measles estimates were taken from WHO Immunization, Vaccines and Biologicals Department.¹⁷ These estimates assume zero deaths for ages 10 years and older. For 5-9 year-olds, we split measles deaths into endemic and epidemic deaths in countries where the measles caused at least 5% of total deaths in any year between 2000-2019 or more in this age group. Endemic measles was identified by fitting either a log-linear or loess model to the number of measles deaths and were accounted for within the UN-IGME all-cause mortality estimates, whereas epidemic measles was the difference between the total and endemic measles deaths, and were added outside the UN-IGME all-cause mortality estimates. Then, they were recombined to get the final measles cause of death fractions presented here.

The following countries had measles deaths that were calculated outside the UN envelope: Afghanistan, Angola, Benin, Burkina Faso, Bangladesh, Bhutan, Botswana, Central African Republic, Côte d'Ivoire, Cameroon, Democratic Republic of the Congo, Congo, Cabo Verde, Djibouti, Algeria, Egypt, Eritrea, Ethiopia, Fiji, Gabon, Ghana, Guinea, Gambia, Guinea-Bissau, Equatorial Guinea, Indonesia, India, Iraq, Cambodia, Lao People's Democratic Republic, Lebanon, Liberia, Madagascar, Mali, Myanmar, Mozambique, Mauritania, Niger, Nigeria, Nepal, Pakistan, Papua New Guinea, Sudan, Senegal, Sierra Leone, Somalia, South Sudan, Sao Tome and Principe, Chad, Togo, Uganda, Viet Nam, Samoa, Yemen, and Zambia.

Webappendix 6.2 The process of squeezing extrapulmonary TB, HIV/AIDS and endemic measles into Other CMPN



Single-cause estimates

Modelled Other CMPN fraction

Webappendix 6.3 Crisis estimates

Crisis estimates, including collective violence, natural disasters, and infectious disease epidemics, were separately produced, and redistributed into causes of death categories depending on the nature of the crisis according to the table below. For a small number of country-years (n = 750) in which collective violence or natural disasters were implausibly high, we capped those cause fractions to the GHE fractions.⁴

Table S6.3. Cause categorization for crisis estimates

| Cause | Type of crisis |
|-----------------------------------|--|
| Collective Violence | Civil war, war, conflict, genocide, invasion, protests, crisis, uprising, insurgency, war spillover, offensive |
| Natural Disasters | Earthquake, cyclone, flood and mudslides, hurricane and landslides, tsunami, forest fires |
| All causes | Unclear (Jordan 2005, Turkey 2016) |
| Other CMPN/measles/HIV/malaria/TB | Ebola/Measles |

Webappendix 7. The GATHER checklist



| Item # | Checklist item | | Reported on section | | | | |
|----------|---|----------------------------------|--|--|--|--|--|
| Objectiv | Objectives and funding | | | | | | |
| 1 | Define the indicator(s), populations (including age, sex, and geog entities), and time period(s) for which estimates were made. | raphic | Introduction | | | | |
| 2 | List the funding sources for the work. | | Abstract | | | | |
| Data Inp | outs | | | | | | |
| For all | data inputs from multiple sources that are synthesized as pa | rt of the study | : | | | | |
| 3 | Describe how the data were identified and how the data were account | essed. | Methods | | | | |
| 4 | Specify the inclusion and exclusion criteria. Identify all ad-hoc ex | clusions. | Methods; Webappendix 3 | | | | |
| 5 | Provide information on all included data sources and their main of For each data source used, report reference information or contact name/institution, population represented, data collection method, data collection, sex and age range, diagnostic criteria or measurement and sample size, as relevant. | year(s) of | Methods; Webappendix 3 | | | | |
| 6 | Identify and describe any categories of input data that have potent important biases (e.g., based on characteristics listed in item 5). | ially | Methods; Webappendix 3 | | | | |
| For da | ta inputs that contribute to the analysis but were not synthesi | zed as part of | the study: | | | | |
| 7 | Describe and give sources for any other data inputs. | | Methods; Webappendices 3 and 6 | | | | |
| For all | data inputs: | | | | | | |
| 8 | Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data. | collected are p GitHub reposi | nts and cause of death data publicly available from the sitory p.com/panchoVG/Mort5to19. | | | | |
| Data ana | ılysis | | | | | | |
| 9 | Provide a conceptual overview of the data analysis method. A dia helpful. | gram may be | Methods; Webappendix 5 | | | | |
| 10 | Provide a detailed description of all steps of the analysis, includin mathematical formulae. This description should cover, as relevant cleaning, data pre-processing, data adjustments and weighting of and mathematical or statistical model(s). | t, data | Methods; Webappendices 4 and 6 | | | | |
| 11 | Describe how candidate models were evaluated and how the final were selected. | Methods; Webappendix 9 | | | | | |
| 12 | Provide the results of an evaluation of model performance, if don't the results of any relevant sensitivity analysis. | e, as well as | Webappendix 9 | | | | |
| 13 | Describe methods for calculating uncertainty of the estimates. Sta sources of uncertainty were, and were not, accounted for in the ur analysis. | te which acertainty | Methods; Webappendix 4 | | | | |

Webappendix 8. Inputs and outputs by estimation methods

| | | Input Data | | Output Estin | mates | |
|------------------------|---------------|-------------------|------------|--------------|-------------------|-----------|
| | Data points | Deaths | Covariates | Countries | Deaths 2019 | Countries |
| 5-9-year-olds | | | | | | |
| High-quality VR data | 2,570 (66.9%) | 461,684 (47.5%) | - | 67 | 19,980 (3.9%) | 67 |
| Low mortality model | 1,041 (27·1%) | 456,853 (47.0%) | 11 | 58 | 22,928 (4·4%) | 51 |
| High mortality model | 230 (6.0%) | 54,013 (5.6%) | 13 | 29 | 457,896 (88.6%) | 76 |
| China | 5,648 | 36,366 | - | 1 | 16,167 (3·1%) | 1 |
| | | | | Total | 516,971 | 195 |
| 10-14-year-olds | | | | | | |
| High-quality VR data | 2,570 (66.6%) | 538,941 (47·1%) | - | 67 | 24,437 (6.6%) | 67 |
| Low mortality model | 1,059 (27·4%) | 533,766 (46.7%) | 12 | 58 | 21,327 (5.8%) | 51 |
| High mortality model | 230 (6.0%) | 71,508 (6·3%) | 13 | 29 | 306,276 (83·2%) | 76 |
| China | 5,648 | 37,207 | - | 1 | 16,111 (4·4%) | 1 |
| | | | | Total | 368,151 | 195 |
| 15-19-year-old females | | | | | | |
| High-quality VR data | 1,285 (51·7%) | 412,694 (48.8%) | - | 67 | 19,773 (8·1%) | 67 |
| Low mortality model | 1,050 (42·2%) | 409,483 (48·4%) | 13 | 57 | 12,768 (5·3%) | 51 |
| High mortality model | 153 (6.2%) | 23,637 (2.8%) | 12 | 20 | 202,095 (83·1%) | 76 |
| China | 5,648 | 43,650 | - | 1 | 8,589 (3.5%) | 1 |
| | | | | Total | 243,225 | 195 |
| 15-19-year-old males | | | | | | |
| High-quality VR data | 1,285 (51.0%) | 1,143,840 (49.6%) | - | 67 | 55,612 (15.8%) | 67 |
| Low mortality model | 1,091 (43·3%) | 1,136,458 (49·3%) | 14 | 58 | 27,391 (7.8%) | 51 |
| High mortality model | 145 (5.8%) | 26,782 (1·2%) | 11 | 17 | 255,152 (72·5%) | 76 |
| China | 5,648 | 18,129 | | | 13,726 (3.9%) | 1 |
| | | | | Total | 351,881 | 195 |
| 5-19-year-olds | | | | | | |
| High-quality VR data | | | | | 119,802 (8·1%) | 67 |
| Low mortality model | | | | | 84,414 (5·7%) | 51 |
| High mortality model | | | | | 1,221,418 (82·5%) | 76 |
| China | | | | | 54,593 (3.7%) | 1 |
| | | | | Total | 1,480,227 | 195 |

^a Percentages calculated within each age-sex group. China is excluded from the percentage calculations for inputs since its data was not included in the modeling.


^b Estimates for China are derived through adjusting empirical data, not modeling (Liu Y, Chu Y, Yeung D *et al.*; unpublished data).

^c Inputs for LMM are high-quality VR country-years with at least 15 total deaths. Countries with less than 15 deaths for the whole period (2000-2019) were not represented in the input data.


Webappendix 9. Model selection process

Identification of LASSO precision parameter λ through cross-validation by estimation methods. Based on out-of-sample prediction with a random effect standard deviation set at $b = 0 \cdot 07$, the best λ , defined as the one that gives the least root mean squared error in the out-of-sample prediction, is marked red in the figures below.

Webappendix 9.1 Cross-validation for low-mortality model (LMM)



Webappendix 9.2 Cross-validation for high-mortality model (HMM)



Webappendix 10. Global and regional cause-specific mortality estimates by age-sex group, 2000-2019

Webappendix 10.1 Data files with global and regional cause-specific mortality estimates

The following CSV (comma separated value) files with mortality estimates are available from the GitHub repository https://github.com/panchoVG/Mort5to19.

Mortality estimates without uncertainty (point estimates)

- 'PointEstimates5to9-Regional.csv': Global and regional all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 5-9 years, 2000-2019.
- 'PointEstimates10to14-Regional.csv': Global and regional all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 10-14 years, 2000-2019.
- 'PointEstimates15to19-Regional.csv': Global and regional all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 15-19 years, 2000-2019.
- 'PointEstimates5to19-Regional.csv': Global and regional all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 5-19 years, 2000-2019.

Mortality estimates with 95% uncertainty intervals

- 'AllCauseUncert-Regional.csv': Global and regional all-cause number of deaths and all-cause mortality rates with 95% uncertainty intervals, 5-9, 10-14 and 15-19 years, 2000-2019.
- 'Uncertainty5to9-Regional.csv': Global and regional cause-specific number of deaths, mortality rates, and mortality fractions with 95% uncertainty intervals for 5-9 years, 2000-2019.
- 'Uncertainty10to14-Regional.csv': Global and regional cause-specific number of deaths, mortality rates, and mortality fractions with 95% uncertainty intervals for 10-14 years, 2000-2019.
- 'Uncertainty15to19-Regional.csv': Global and regional cause-specific number of deaths, mortality rates, and mortality fractions with 95% uncertainty intervals for 15-19 years, 2000-2019
- 'Uncertainty5to19-Regional.csv': Global and regional cause-specific number of deaths and mortality fractions with 95% uncertainty intervals for 5 to 19 years, 2000-2019.
- 'GlobalAARR.csv': Global cause-specific annual average rate of reduction (AARR) 2000-2019 with 95% uncertainty intervals, 5-9, 10-14 and 15-19 years.

Webappendix 10.2 Global and regional leading causes of death 5-19 years in 2019

Table S10.2. Global and regional leading causes of death 5-19 years in 2019

| Region | Cause | Number of deaths | Fraction |
|---------------------------------|------------------------|---------------------------|--------------------|
| World | Road traffic injuries | 115,843 (110,672-125,054) | 7.8% (7.5-8.1%) |
| West and central Africa | Malaria | 63,205 (53,960-75,377) | 14·4% (12·9-15·7%) |
| Eastern and Southern Africa | HIV/AIDS | 19,883 (17,267-24,673) | 6.6% (5.9-7.4%) |
| Middle East and North Africa | Collective violence | 14,359 (11,442-18,436) | 20·1% (17-23·3%) |
| South Asia | Road traffic injuries | 30,081 (26,047-36,080) | 8·2% (7·6-8·7%) |
| East Asia and Pacific | Neoplasms | 19,972 (17,242-24,521) | 12·4% (11·6-13·4%) |
| Latin America and Caribbean | Interpersonal violence | 18,029 (17,155-19,021) | 21.6% (20.6-22.4%) |
| North America | Road traffic injuries | 3,741 (3,490-3,998) | 20.8% (20.1-21.4%) |
| Eastern Europe and central Asia | Neoplasms | 4,221 (4,112-4,334) | 16.6% (16.3-16.9%) |
| Western Europe | Neoplasms | 2,050 (1,968-2,147) | 19·8% (19·1-20·5%) |

Note: Values between parenthesis denote 95% uncertainty intervals.

Webappendix 10.3 Global and regional causes of mortality fractions by age-sex group in 2019

The following table contains the data for Figure 3 from the main manuscript.

Table S10.3. Global and regional causes of mortality fractions by age-sex group in 2019


| Region | Cause of death | 5 to 9 | 10 to 14 | 15 to 19 females | 15 to 19 males |
|----------------------|------------------------|--------------|----------------|------------------|-------------------|
| | Maternal | NA | NA | 5.00% | NA |
| | Measles | 4.21% | NA | NA | NA |
| | HIV/AIDS | 1.62% | 3.28% | 2.45% | 2.03% |
| | LRI | 6.55% | 6.80% | NA | NA |
| | TB | 4.33% | 2.12% | 6.32% | 7.18% |
| | Diarrhoeal | 9.99% | 5.72% | NA | NA |
| | Malaria | 9.66% | 8.58% | NA | NA |
| | Other CMPN | 16.82% | 16.82% | 11.70% | 11.72% |
| | Congenital | 3.40% | NA | NA | NA |
| W. 11 | Cardiovascular | NA | NA | 6.97% | 6.16% |
| World | Digestive system | 3.12% | 2.88% | 5.32% | 4.74% |
| | Neoplasms | 5.50% | 7.28% | 7.52% | 6.20% |
| | Other NCD | 13.10% | 15.86% | 19.37% | 12.15% |
| | Interpersonal violence | NA | NA | 4.29% | 12.25% |
| | Self-harm | NA | NA | 13.42% | 8.31% |
| | Drowning | 6.40% | 6.41% | 1.86% | 4.61% |
| | RTI | 5.41% | 6.12% | 6.81% | 13.86% |
| | Other injuries | 8.86% | 16.45% | 7.55% | 8.79% |
| | Natural disasters | 0.06% | 0.08% | 0.05% | 0.07% |
| | Collective violence | 0.98% | 1.58% | 1.36% | 1.93% |
| | Maternal | NA | NA | 6.73% | NA |
| | Measles | 5.07% | NA | NA | NA |
| | HIV/AIDS | 1.49% | 3.84% | 2.87% | 3.04% |
| | LRI | 8.73% | 9.46% | NA | NA |
| | TB | 3.20% | 1.50% | 8.03% | 12.24% |
| | Diarrhoeal | 13.48% | 11.36% | NA | NA |
| | Malaria | 19.18% | 22.17% | NA | NA |
| | Other CMPN | 25.40% | 29.39% | 25.53% | 20.93% |
| | Congenital | 2.79% | NA | NA | NA |
| West and central | Cardiovascular | NA | NA | 8.08% | 6.29% |
| Africa | Digestive system | 1.96% | 1.70% | 6.03% | 5.11% |
| | Neoplasms | 2.47% | 2.34% | 4.40% | 4.81% |
| | Other NCD | 5.42% | 8.08% | 13.14% | 9.81% |
| | Interpersonal violence | NA | NA | 2.70% | 6.25% |
| | Self-harm | NA | NA 2 0 40 (| 9.01% | 6.91% |
| | Drowning | 2.91% | 2.94% | 1.14% | 3.90% |
| | RTI | 4.36% | 3.53% | 5.18% | 10.76% |
| | Other injuries | 3.22% | 3.21% | 6.26% | 8.19% |
| | Natural disasters | 0.00% | 0.00% | 0.00% | 0.00% |
| | Collective violence | 0.30% | 0.47% | 0.89% | 1.74% |
| | Maternal | NA 2.670/ | NA NA | 4.85% | NA NA |
| | Measles | 3.67% | NA 0.03% | NA 8 420/ | NA |
| Eastern and Southern | HIV/AIDS | 3.75% | 9.93% | 8.43% | 6.66% |
| Africa | LRI TB | 8.63% | 11.47% | NA 7.40% | NA 7 920/ |
| | Diarrhoeal | 3.73% | 1.87% | 7.40% | 7.83% |
| | | 10.43% | 6.10% | NA NA | NA NA |
| | Malaria | 9.12% | 9.06% | NA | NA |

| Region | Cause of death | 5 to 9 | 10 to 14 | 15 to 19 females | 15 to 19 males |
|-----------------------|------------------------|--------------|--------------|------------------|----------------|
| | Other CMPN | 17.94% | 18.96% | 14.44% | 17.97% |
| | Congenital | 2.82% | NA | NA | NA |
| | Cardiovascular | NA | NA | 7.16% | 6.53% |
| | Digestive system | 3.18% | 2.54% | 6.20% | 5.66% |
| | Neoplasms | 3.75% | 5.29% | 5.62% | 5.31% |
| | Other NCD | 14.10% | 14.03% | 17.10% | 10.89% |
| | Interpersonal violence | NA | NA | 3.69% | 5.49% |
| | Self-harm | NA | NA | 11.23% | 7.66% |
| | Drowning | 5.51% | 6.02% | 1.41% | 4.31% |
| | RTI | 4.54% | 4.60% | 4.74% | 11.90% |
| | Other injuries | 8.55% | 9.71% | 7.15% | 8.97% |
| | Natural disasters | 0.10% | 0.14% | 0.08% | 0.10% |
| | Collective violence | 0.18% | 0.28% | 0.49% | 0.72% |
| | Maternal | NA | NA | 3.77% | NA |
| | Measles | 2.38% | NA | NA | NA |
| | HIV/AIDS | 0.12% | 0.10% | 0.13% | 0.07% |
| | LRI | 5.78% | 4.30% | NA | NA |
| | TB | 1.19% | 0.42% | 1.49% | 1.00% |
| | Diarrhoeal | 3.06% | 1.71% | NA | NA |
| | Malaria | 0.24% | 0.17% | NA NA | NA |
| | Other CMPN | 8.78% | 9.00% | 6.72% | 10.91% |
| | Congenital | 6.02% | 9.0076 NA | 0.7276 NA | 10.9170 NA |
| Middle East and | Cardiovascular | 0.0276 NA | NA NA | 4.58% | 4.67% |
| North Africa | | 2.19% | 1.72% | 3.13% | 2.26% |
| Norui Airica | Digestive system | 13.47% | 13.24% | 9.33% | 6.93% |
| | Neoplasms | | | | |
| | Other NCD | 16.05% | 20.22% | 26.77% | 12.87% |
| | Interpersonal violence | NA | NA | 6.81% | 16.79% |
| | Self-harm | NA | NA | 11.22% | 5.61% |
| | Drowning | 5.31% | 3.88% | 0.95% | 3.48% |
| | RTI | 7.16% | 5.72% | 5.23% | 11.86% |
| | Other injuries | 10.72% | 13.44% | 2.99% | 4.20% |
| | Natural disasters | 0.03% | 0.03% | 0.02% | 0.02% |
| | Collective violence | 17.49% | 26.06% | 16.88% | 19.34% |
| | Maternal | NA | NA | 4.70% | NA |
| | Measles | 4.85% | NA | NA | NA |
| | HIV/AIDS | 0.21% | 0.35% | 0.04% | 0.04% |
| | LRI | 1.91% | 2.98% | NA | NA |
| | TB | 7.87% | 3.48% | 7.40% | 9.55% |
| | Diarrhoeal | 8.65% | 3.04% | NA | NA |
| | Malaria | 0.39% | 0.42% | NA | NA |
| | Other CMPN | 6.90% | 9.43% | 4.00% | 8.14% |
| | Congenital | 2.71% | NA | NA | NA |
| Courth Asia | Cardiovascular | NA | NA | 6.19% | 7.22% |
| South Asia | Digestive system | 5.73% | 4.70% | 6.03% | 7.18% |
| | Neoplasms | 5.02% | 6.93% | 7.54% | 5.90% |
| | Other NCD | 20.20% | 16.07% | 21.45% | 13.67% |
| | Interpersonal violence | NA | NA | 4.27% | 9.03% |
| | Self-harm | NA | NA | 18.88% | 8.65% |
| | Drowning | 12.44% | 9.56% | 2.44% | 4.98% |
| | RTI | 5.54% | 7.84% | 5.94% | 13.84% |
| | Other injuries | 17.06% | 34.74% | 10.21% | 10.76% |
| | Natural disasters | 0.05% | 0.05% | 0.03% | 0.04% |
| | Collective violence | 0.46% | 0.42% | 0.88% | 1.00% |
| | Maternal | NA | NA | 3.64% | |
| East Asia and Pacific | | 3.40% | NA NA | | NA NA |
| | Measles | J.4U% | INA | NA | NA |


| Region | Cause of death | 5 to 9 | 10 to 14 | 15 to 19 | 15 to 19 |
|-------------------|------------------------|----------------|----------------|-----------------|-------------|
| | | | | females | males |
| | HIV/AIDS | 1.19% | 0.82% | 0.41% | 0.50% |
| | LRI | 3.54% | 3.78% | NA | NA |
| | TB | 5.64% | 2.90% | 3.95% | 6.16% |
| | Diarrhoeal | 4.15% | 1.42% | NA | NA NA |
| | Malaria Other CMPN | 0.38% 8.07% | 0.25% 8.03% | NA 4.54% | 6.05% |
| | Congenital | 5.40% | 8.03% NA | 4.34% NA | 0.03% NA |
| | Cardiovascular | 3.40% NA | NA NA | 8.38% | 7.41% |
| | Digestive system | 2.69% | 2.94% | 3.23% | 4.05% |
| | Neoplasms | 12.93% | 15.62% | 13.16% | 8.82% |
| | Other NCD | 20.01% | 26.61% | 24.53% | 14.57% |
| | Interpersonal violence | NA | NA | 4.10% | 10.54% |
| | Self-harm | NA | NA | 13.62% | 9.10% |
| | Drowning | 11.01% | 10.92% | 3.49% | 6.97% |
| | RTI | 8.81% | 8.88% | 9.26% | 15.74% |
| | Other injuries | 12.51% | 17.56% | 7.51% | 9.82% |
| | Natural disasters | 0.19% | 0.17% | 0.11% | 0.14% |
| | Collective violence | 0.07% | 0.09% | 0.08% | 0.12% |
| | Maternal | NA | NA | 5.95% | NA |
| | Measles | 0.00% | NA | NA | NA |
| | HIV/AIDS | 0.63% | 0.67% | 1.12% | 0.50% |
| | LRI | 5.66% | 4.33% | NA | NA |
| | TB | 1.01% | 0.46% | 1.35% | 0.55% |
| | Diarrhoeal | 2.80% | 0.99% | NA | NA |
| | Malaria | 0.03% | 0.04% | NA | NA |
| | Other CMPN | 9.05% | 7.10% | 8.33% | 4.78% |
| | Congenital | 7.22% | NA | NA | NA |
| Latin America and | Cardiovascular | NA | NA | 5.97% | 3.39% |
| Caribbean | Digestive system | 3.07% | 2.90% | 3.55% | 1.49% |
| | Neoplasms | 18.12% | 15.68% | 10.96% | 5.69% |
| | Other NCD | 24.35% | 30.01% | 22.76% | 9.33% |
| | Interpersonal violence | NA | NA | 11.16% | 40.91% |
| | Self-harm | NA | NA | 9.61% | 6.33% |
| | Drowning | 4.96% | 5.13% | 1.29% | 3.59% |
| | RTI | 9.58% | 10.46% | 12.72% | 16.29% |
| | Other injuries | 13.08% | 21.79% | 4.98% | 7.02% |
| | Natural disasters | 0.44% | 0.43% | 0.26% | 0.13% |
| | Collective violence | 0.00% | 0.00% | 0.00% | 0.00% |
| | Maternal | NA | NA | 0.98% | NA |
| | Measles | 0.00% | NA | NA | NA |
| | HIV/AIDS | 0.00% | 0.02% | 0.07% | 0.02% |
| | LRI | 2.25% | 1.49% | NA | NA |
| | TB | 0.01% | 0.00% | 0.04% | 0.01% |
| | Diarrhoeal | 0.31% | 0.19% | NA | NA |
| | Malaria | 0.00% | 0.00% | NA | NA 1 2004 |
| NT ALA | Other CMPN | 4.18% | 2.80% | 2.62% | 1.38% |
| North America | Congenital | 8.50% | NA NA | NA 4.419/ | NA 2 160/ |
| | Cardiovascular | NA 1.520/ | NA 1 600/ | 4.41% | 3.16% |
| | Digestive system | 1.52% | 1.68% | 1.12% | 0.58% |
| | Neoplasms Other NCD | 19.58% | 15.35% | 8.38% | 5.39% |
| | Other NCD | 27.75% | 33.20% | 24.40% 7.56% | 16.62% |
| | Interpersonal violence | NA NA | NA NA | 7.56% | 19.10% |
| | Self-harm | NA 5 30% | NA 3 21% | 18.05% | 22.74% |
| | Drowning | 5.30% | 3.21% | 0.73% | 2.75% |
| | RTI | 14.35% | 13.81% | 27.85% | 22.60% |

| Region | Cause of death | 5 to 9 | 10 to 14 | 15 to 19 females | 15 to 19 males |
|--------------------|------------------------|--------|----------|------------------|-------------------|
| | Other injuries | 16.00% | 28.15% | 3.73% | 5.59% |
| | Natural disasters | 0.26% | 0.10% | 0.05% | 0.05% |
| | Collective violence | 0.00% | 0.00% | 0.00% | 0.00% |
| | Maternal | NA | NA | 1.85% | NA |
| | Measles | 0.10% | NA | NA | NA |
| | HIV/AIDS | 0.91% | 0.38% | 0.54% | 0.20% |
| | LRI | 5.90% | 5.64% | NA | NA |
| | TB | 2.33% | 0.63% | 1.69% | 1.25% |
| | Diarrhoeal | 1.41% | 0.66% | NA | NA |
| | Malaria | 0.00% | 0.00% | NA | NA |
| | Other CMPN | 6.96% | 4.95% | 5.89% | 4.62% |
| | Congenital | 8.93% | NA | NA | NA |
| Eastern Europe and | Cardiovascular | NA | NA | 7.06% | 5.35% |
| central Asia | Digestive system | 2.49% | 2.46% | 2.22% | 1.28% |
| | Neoplasms | 21.31% | 18.95% | 16.28% | 11.30% |
| | Other NCD | 23.13% | 33.55% | 23.87% | 15.10% |
| | Interpersonal violence | NA | NA | 4.70% | 6.78% |
| | Self-harm | NA | NA | 11.69% | 13.70% |
| | Drowning | 6.27% | 6.85% | 1.90% | 6.07% |
| | RTI | 9.18% | 8.68% | 16.13% | 24.28% |
| | Other injuries | 10.71% | 16.88% | 5.83% | 9.37% |
| | Natural disasters | 0.01% | 0.02% | 0.02% | 0.02% |
| | Collective violence | 0.36% | 0.33% | 0.33% | 0.69% |
| | Maternal | NA | NA | 0.18% | NA |
| | Measles | 0.02% | NA | NA | NA |
| | HIV/AIDS | 0.01% | 0.01% | 0.16% | 0.04% |
| | LRI | 2.90% | 2.55% | NA | NA |
| | TB | 0.03% | 0.07% | 0.02% | 0.05% |
| | Diarrhoeal | 0.34% | 0.13% | NA | NA |
| | Malaria | 0.02% | 0.01% | NA | NA |
| | Other CMPN | 3.49% | 2.67% | 4.50% | 2.86% |
| | Congenital | 11.12% | NA | NA | NA |
| | Cardiovascular | NA | NA | 5.76% | 4.67% |
| Western Europe | Digestive system | 1.47% | 1.56% | 1.37% | 0.85% |
| | Neoplasms | 30.80% | 25.73% | 17.65% | 12.79% |
| | Other NCD | 31.10% | 40.77% | 28.44% | 20.78% |
| | Interpersonal violence | NA | NA | 2.17% | 2.42% |
| | Self-harm | NA | NA | 16.14% | 19.27% |
| | Drowning | 2.60% | 2.57% | 0.94% | 3.63% |
| | RTI | 6.74% | 8.71% | 16.38% | 23.23% |
| | Other injuries | 9.11% | 14.96% | 6.17% | 9.35% |
| | Natural disasters | 0.21% | 0.23% | 0.12% | 0.07% |
| | Collective violence | 0.02% | 0.2376 | 0.00% | 0.00% |
| | Concentre violence | 0.04/0 | 0.0070 | 0.0070 | 0.0070 |


Webappendix 10.4 Regional cause-specific mortality rates by age-sex group, time trends 2000-2019









Eastern and Southern Africa




Middle East and North Africa




East Asia and Pacific




Latin America and Caribbean




Eastern Europe and central Asia



North America



Western Europe



Webappendix 11. National cause-specific mortality estimates by age-sex group, 2000-2019

Webappendix 11.1 Data files with national cause-specific mortality estimates

The following CSV (comma separated value) files with mortality estimates are available from the GitHub repository https://github.com/panchoVG/Mort5to19.

Mortality estimates without uncertainty (point estimates)

- 'PointEstimates5to9-National.csv': National all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 5-9 years, 2000-2019.
- 'PointEstimates10to14-National.csv': National all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 10-14 years, 2000-2019.
- 'PointEstimates15to19-National.csv': National all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 15-19 years, 2000-2019.
- 'PointEstimates5to19-National.csv': National all-cause number of deaths, all-cause mortality rates, and cause-specific mortality fractions for 5-19 years, 2000-2019.

Mortality estimates with 95% uncertainty intervals

- 'AllCauseUncert-National.csv': National all-cause number of deaths and all-cause mortality rates with 95% uncertainty intervals, 5-9, 10-14 and 15-19 years, 2000-2019.
- 'Uncertainty5to9-National.csv': National cause-specific number of deaths, mortality rates, and mortality fractions with 95% uncertainty intervals for 5-9 years, 2000-2019.
- 'Uncertainty10to14-National.csv': National cause-specific number of deaths, mortality rates, and mortality fractions with 95% uncertainty intervals for 10-14 years, 2000-2019.
- 'Uncertainty15to19-National.csv': National cause-specific number of deaths, mortality rates, and mortality fractions with 95% uncertainty intervals for 15-19 years, 2000-2019.

Webappendix 11.2 Countries with the highest number of deaths in 2019


Table S11.2. Top 10 countries with highest burden in 2019


| # | ISO3 | WHO name | 5 to 19 | 5 to 9 | 10 to 14 | 15 to 19 females | 15 to 19 males |
|----|------|--|------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| 1 | IND | India | 233,892 (199,891-270,701) | 65,413 (54,728-76,120) | 68,681 (43,872-98,054) | 49,255 (39,237-59,623) | 50,542 (40,262-61,180) |
| 2 | NGA | Nigeria | 157,340 (120,584-197,615) | 80,995 (65,229-99,534) | 39,993 (11,042-73,632) | 16,935 (11,045-25,681) | 19,419 (12,664-29,446) |
| 3 | COD | Democratic Republic of the Congo | 91,675 (67,070-120,212) | 36,530 (26,147-48,208) | 22,061 (5,149-40,831) | 14,601 (8,102-22,917) | 18,483 (10,255-29,009) |
| 4 | PAK | Pakistan | 66,598 (41,809-111,674) | 22,793 (15,134-30,080) | 17,567 (0-61,117) | 11,299 (6,056-18,007) | 14,939 (8,008-23,810) |
| 5 | CHN | China | 54,593 (42,895-73,731) | 16,167 (10,492-22,256) | 16,111 (8,140-31,604) | 8,589 (5,718-12,145) | 13,726 (9,138-19,409) |
| 6 | ЕТН | Ethiopia | 51,279 (31,852-73,339) | 17,497 (9,623-26,374) | 13,204 (0-30,407) | 8,020 (4,387-12,448) | 12,558 (6,870-19,491) |
| 7 | IDN | Indonesia | 45,934 (33,659-64,431) | 14,772 (10,584-18,942) | 9,017 (1,404-22,543) | 8,273 (4,970-12,561) | 13,872 (8,333-21,060) |
| 8 | BGD | Bangladesh | 43,807 (32,428-61,188) | 13,77 (10,811-17,825) | 10,064 (1,596-24,079) | 9,692 (6,678-13,725) | 10,574 (7,286-14,974) |
| 9 | UGA | Uganda | 32,001 (23,263-42,270) | 11,937 (7,963-16,175) | 6,399 (242-13,316) | 5,195 (3,353-7,736) | 8,470 (5,467-12,612) |
| 10 | TZA | United Republic of Tanzania | 27,562 (19,425-48,491) | 13,804 (8,500-17,571) | 5,009 (0-25,427) | 3,587 (2,191-5,506) | 5,162 (3,152-7,922) |

Note: Data are number of deaths (95% uncertainty intervals).


Webappendix 11.3 Cause-specific mortality rates by age-sex group in India, Nigeria and Democratic Republic of Congo, time trends 2000-2019

Time trends of the cause-specific mortality rates for the three countries with highest burden in 2019.





Democratic Republic of the Congo



References

- 1. World Health Organization. Department of Data and Analytics (DNA), Division of Data, Analytics and Delivery for Impact (DNI). WHO methods and data sources for country-level causes of death 2000-2019. Geneva, 2020.
- 2. United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels and trends in child mortality. Report 2020, Estimates developed by the United Nations Inter-agency Group for Child Mortality Estimation. New York, NY: United Nations Children's Fund, 2020.
- 3. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. *Lancet* 2016; **388**(10063): 3027-35.
- 4. WHO. Global Health Estimates 2016: Deaths by cause, age, sex, by country and by region, 2000-2016. Geneva: World Health Organization, 2018.
- 5. GBD 2017 Cause of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1736-88.
- 6. Stevens GA, Finucane MM, Paciorek CJ, et al. Trends in mild, moderate, and severe stunting and underweight, and progress towards MDG 1 in 141 developing countries: a systematic analysis of population representative data. *Lancet* 2012; **380**(9844): 824-34.
- 7. Buchard V, Randles C, Da Silva A, et al. The MERRA-2 aerosol reanalysis, 1980 onward. Part II: Evaluation and case studies. *Journal of Climate* 2017; **30**(17): 6851-72.
- 8. DistillerSR: A web-based systematic review product. https://www.evidencepartners.com/products/distillersr-systematic-review-software (accessed Apr 14, 2021).
- 9. Mulick AR, Oza S, Prieto-Merino D, Villavicencio F, Cousens S, Perin J. A Bayesian hierarchical model with integrated covariate selection and misclassification matrices to estimate neonatal and child causes of death. *medRxiv* 2021; published online Feb 2021. https://doi.org/10.1101/2021.02.10.21251488 (preprint).
- 10. Park T, Casella G. The Bayesian Lasso. J Am Stat Assoc 2008; 103(482): 681-6.
- 11. Masquelier B, Hug L, Sharrow D, et al. Global, regional, and national mortality trends in youth aged 15–24 years between 1990 and 2019: a systematic analysis. *Lancet Glob Heath* 2021; **9**(4): e409-17.
- 12. United Nations Department of Economic and Social Affairs. World Population Prospects 2019. 2019. https://population.un.org/wpp/ (accessed Apr 24, 2021).
- 13. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis 3rd edition. New York, NY: Chapman and Hall/CRC; 2013.
- 14. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. URL: https://www.r-project.org/.
- 15. Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. 3rd International Workshop on Distributed Statistical Computing. 2003. https://www.r-project.org/conferences/DSC-2003/Proceedings/ (accessed Feb 27, 2019).
- 16. Su YS, Yajima M. R2jags: Using R to run 'JAGS'. R package version 0.7-1. 2020. https://cran.r-project.org/web/packages/R2jags/ (accessed Feb 23, 2021).
- 17. Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. *Lancet* 2012; **379**(9832): 2173-8.